VISION

PentixaPharm is committed to developing the innovative theranostic pair PentixaFor and PentixaTher. PentixaFor and PentixaTher are two-small peptide-based radiopharmaceuticals which specifically target the CXCR4-receptor expressed in most fast progressing diseases such as hematological and solid cancers as well as cardiovascular malignancies.

 

MANAGEMENT TEAM

With a solid history of building successful radiopharmaceutical start-ups, the PentixaPharm management  team incorporates personal experience in all key functions of an early stage radiopharmaceutical development  company: clinical development, manufacturing as well as organizational and financial set-up.

DR. HAKIM BOUTERFA   
CLINIC

Managing Director,
PentixaPharm GmbH

Co-Founder, Managing Director,
1717 LSV GmbH

Co-Founder, former Managing Director, OctreoPharm Sciences GmbH

Former Vice President Europe, Molecular Insight Pharmaceuticals GmbH

Former Global Medical Director Sandostatin, Novartis Pharma AG, (revenues > $ 1 BN p.a.)
Done >50 % coordinated > 200 clinical studies in Phase I – IV

Studied Human Biology (PhD) and Medicine, Universities Marburg & Göttingen

ANNA STEEGER   
FINANCE

Managing Director,
PentixaPharm GmbH

Co-Founder, Managing Director,
1717 LSV GmbH

Former Portfolio Manager,
Full Power of Attorney, Eckert Life Science Accelerator GmbH

Former Head of Finance & Administation, OctreoPharm Sciences GmbH

Founder Polyventures GmbH 

Former Member of Board of Directors, EZ Bebig s.a.

Studied Business (Master), Universities Sydney & Zurich

DR. JENS KAUFMANN   
MANUFACTURING

Managing Director,
PentixaPharm GmbH

Co-Founder, Managing Director,
1717 LSV GmbH

Former Director RP Development, Ipsen AG

Former Head RP Development, OctreoPharm Sciences GmbH

Former Head of Chemical Product and Process Development,
Eckert & Ziegler AG

Studied Chemistry (PhD), 
Technical University of Berlin